Literature DB >> 10318951

Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.

K M Lau1, S C Mok, S M Ho.   

Abstract

Our understanding of the roles played by sex hormones in ovarian carcinogenesis has been limited by a lack of data concerning the mode of sex hormone action in human ovarian surface epithelial (HOSE) cells, the tissue of origin of >90% of ovarian cancers. We have compared the relative abundance of estrogen receptor (ER)alpha, ERbeta, progesterone receptor (PR), and androgen receptor (AR) mRNA in four primary cultures of HOSE cells obtained from postmenopausal women to those found in late serous adenocarcinoma primary cell cultures and established ovarian cancer cell lines. We observed coexpression of ERalpha and ERbeta mRNA along with AR and PR transcripts in normal HOSE cells and disruption of ERalpha mRNA expression as well as dramatic down-regulation of PR and AR transcript expression in most ovarian cancer cells. In contrast, levels of ERbeta mRNA were unaffected by the malignant state. Additionally, a novel mutation involving a 32-bp deletion in exon 1 of ERalpha transcripts was detected in the SKOV3 cell line. This mutation would explain why SKOV3 was reported to be ER-positive but estrogen-insensitive. Taken together, these findings suggest that estrogens, signaling via either or both ER subtypes, may play an indispensable role in regulating normal HOSE cell functions. Therefore, loss of ERalpha, PR, and AR mRNA expression in HOSE cells may be responsible for neoplastic transformation in this cell type. In contrast, the roles played by ERbeta in normal and malignant HOSE cells remain elusive. Finally, the coexistence of mutated ERalpha mRNA and normal ERbeta transcripts in SKOV3 argues in favor of a dependency of ERbeta action on functional ERalphas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10318951      PMCID: PMC21927          DOI: 10.1073/pnas.96.10.5722

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors.

Authors:  M I Edelson; C C Lau; C V Colitti; W R Welch; D A Bell; R S Berkowitz; S C Mok
Journal:  Oncogene       Date:  1998-01-15       Impact factor: 9.867

2.  Responses in the brain of estrogen receptor alpha-disrupted mice.

Authors:  P J Shughrue; D B Lubahn; A Negro-Vilar; K S Korach; I Merchenthaler
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

3.  Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues.

Authors:  A W Brandenberger; M K Tee; R B Jaffe
Journal:  J Clin Endocrinol Metab       Date:  1998-03       Impact factor: 5.958

4.  Rat estrogen receptor-alpha and -beta, and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats.

Authors:  K M Lau; I Leav; S M Ho
Journal:  Endocrinology       Date:  1998-01       Impact factor: 4.736

5.  Cancer incidence in a cohort of infertile women.

Authors:  B Modan; E Ron; L Lerner-Geva; T Blumstein; J Menczer; J Rabinovici; G Oelsner; L Freedman; S Mashiach; B Lunenfeld
Journal:  Am J Epidemiol       Date:  1998-06-01       Impact factor: 4.897

6.  Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen.

Authors:  K B Horwitz; Y Koseki; W L McGuire
Journal:  Endocrinology       Date:  1978-11       Impact factor: 4.736

7.  Elevated progesterone levels in serum and ovarian venous blood in patients with ovarian tumors.

Authors:  P K Heinonen; T Koivula; P Pystynen
Journal:  Acta Obstet Gynecol Scand       Date:  1985       Impact factor: 3.636

Review 8.  Estrogen receptor beta: re-evaluation of estrogen and antiestrogen signaling.

Authors:  V Giguère; A Tremblay; G B Tremblay
Journal:  Steroids       Date:  1998 May-Jun       Impact factor: 2.668

9.  Ovarian and peripheral androgen and oestrogen levels in post-menopausal women: correlations with ovarian histology.

Authors:  A Lucisano; N Russo; M G Acampora; A Fabiano; M Fattibene; E Parlati; E Maniccia; S Dell'Acqua
Journal:  Maturitas       Date:  1986-03       Impact factor: 4.342

10.  Ovarian and peripheral plasma levels of progestogens, androgens and oestrogens in post-menopausal women.

Authors:  A Lucisano; M G Acampora; N Russo; E Maniccia; A Montemurro; S Dell'Acqua
Journal:  Maturitas       Date:  1984-07       Impact factor: 4.342

View more
  81 in total

1.  Increased proteasome-dependent degradation of estrogen receptor-alpha by TGF-beta1 in breast cancer cell lines.

Authors:  Trevor A Petrel; Robert W Brueggemeier
Journal:  J Cell Biochem       Date:  2003-01-01       Impact factor: 4.429

2.  Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance.

Authors:  Katia Meirelles; Leo Andrew Benedict; David Dombkowski; David Pepin; Frederic I Preffer; Jose Teixeira; Pradeep Singh Tanwar; Robert H Young; David T MacLaughlin; Patricia K Donahoe; Xiaolong Wei
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-27       Impact factor: 11.205

Review 3.  Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis.

Authors:  Gwendal Lazennec
Journal:  Cancer Lett       Date:  2006-01-18       Impact factor: 8.679

4.  A bifunctional platinum(II) antitumor agent that forms DNA adducts with affinity for the estrogen receptor.

Authors:  Eunsuk Kim; Peter T Rye; John M Essigmann; Robert G Croy
Journal:  J Inorg Biochem       Date:  2008-10-26       Impact factor: 4.155

Review 5.  Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.

Authors:  Jennifer R Ribeiro; Richard N Freiman
Journal:  J Steroid Biochem Mol Biol       Date:  2014-02-22       Impact factor: 4.292

6.  Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens.

Authors:  Courtney L Andersen; Matthew J Sikora; Michelle M Boisen; Tianzhou Ma; Alec Christie; George Tseng; Yongseok Park; Soumya Luthra; Uma Chandran; Paul Haluska; Gina M Mantia-Smaldone; Kunle Odunsi; Karen McLean; Adrian V Lee; Esther Elishaev; Robert P Edwards; Steffi Oesterreich
Journal:  Clin Cancer Res       Date:  2017-01-10       Impact factor: 12.531

7.  The role of activin A and Akt/GSK signaling in ovarian tumor biology.

Authors:  Thuy-Vy Do; Lena A Kubba; Monica Antenos; Alfred W Rademaker; Charles D Sturgis; Teresa K Woodruff
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

8.  Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival.

Authors:  Björn Nodin; Nooreldin Zendehrokh; Jenny Brändstedt; Elise Nilsson; Jonas Manjer; Donal J Brennan; Karin Jirström
Journal:  J Ovarian Res       Date:  2010-06-17       Impact factor: 4.234

9.  Androgen receptor protein levels are significantly reduced in serous ovarian carcinomas compared with benign or borderline disease but are not altered by cancer stage or metastatic progression.

Authors:  Miriam S Butler; Carmela Ricciardelli; Wayne D Tilley; Theresa E Hickey
Journal:  Horm Cancer       Date:  2013-02-27       Impact factor: 3.869

10.  Combined application of 17beta-estradiol and progesterone enhance vascular endothelial growth factor and surfactant protein expression in cultured embryonic lung cells of mice.

Authors:  Andreas Trotter; Markus Kipp; Roland Matthias Schrader; Cordian Beyer
Journal:  Int J Pediatr       Date:  2009-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.